Regression of left ventricular hypertrophy in human hypertension with irbesartan

Journal of Hypertension

Volumn 19, Issue 6, 2001, Pages 1167-1176

  Malmqvist, Karin ^a   Kahan, Thomas ^a,f   Edner, Magnus ^a   Held, Claes ^a   Hägg, Anders ^b   Lind, Lars ^b   Müller Brunotte, Richard ^a   Nyström, Fredrik ^c   Öhman, K Peter ^c   Osbakken, Mary D ^d   Östergren, Jan ^e  

^a DANDERYD HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c University of Health Science   (Sweden)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Angiotensin; Atenolol; Echocardiography; Human; Hypertension; Hypertrophy; Irbesartan

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; PLACEBO;

ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SEX DIFFERENCE; SINGLE BLIND PROCEDURE;

EID: 0035007259     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200106000-00023     Document Type: Article

References (39)

1. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men
2. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
3. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment
4. Prognostic significance of serial changes in left ventricular mass in essential hypertension
5. Hypertensive cardiac hypertrophy: Pathophysiological and clinical characteristics
6. Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables
7. Ambulatory blood pressure monitoring and echocardiographic left ventricular wall thickness and mass
8. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension
9. The heart in hypertension
10. Corcoran Lecture. Sympathetic hyperactivity and coronary risk in hypertension
11. Cardioreparation and the concept of modulating cardiovascular structure and function
12. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome
13. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients
14. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system
15. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system
16. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension?
17. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults
18. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension
19. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
20. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)
21. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects
22. Dose-related efficacy of irbesartan for hypertension: An integrated analysis
23. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension
24. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
25. Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy
26. Prognosis of left ventricular geometric patterns in the Framingham Heart Study
27. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on quantitation of two-dimensional echocardiograms
28. Atrioventricular valve plane displacement in healthy persons. An echocardiographic study
29. Rate and extent of left ventricular hypertrophy regression: A comparison of angiotensin II blockade with irbesartan and beta-blockade
30. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight
31. Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle
32. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats
33. Angiotensin II receptor blockade and end-organ protection: Pharmacological rationale and evidence
34. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension
35. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
36. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension
37. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension
38. Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension
39. Comparative safety and tolerability of angiotensin II receptor antagonists